Literature DB >> 30549259

Impact of high- versus low-risk genotype on sinonasal radiographic disease in cystic fibrosis.

Ashleigh A Halderman1, Stella Lee2, Nyall R London3, Andrew Day1, Raksha Jain4, John A Moore2, Sandra Y Lin3.   

Abstract

OBJECTIVE: Understanding of how specific mutations impact the cystic fibrosis transmembrane conductance regulator (CFTR) protein has given rise to the classification of CF patients into low-risk and high-risk genotypes. Few prior studies have investigated differences in sinonasal disease between low-risk and high-risk CF genotypes. This multi-institutional review aimed to evaluate radiographic sinus disease severity based on genotype.
METHODS: A review was conducted on adult patients with CF evaluated between 2005 to 2017 at three academic institutions. Data including age, gender, CFTR mutation, and presence of a maxillofacial/sinus computed tomography scan was collected. A modified Lund-Mackay score (MLMS) was assigned to each scan, and the presence of sinus aplasia or hypoplasia was determined. Patients were further grouped depending on genotype into low- or high-risk for comparison.
RESULTS: A total of 126 patients were included with 99 patients in the high-risk and 21 in the low-risk groups. The high-risk group had significantly higher MLMS than the low-risk group (mean 13.88 vs. 8.06, P < 0.0001, 95% CI -8.196 to -3.462) The rate of frontal (P < 0.01), maxillary (P = 0.04), and sphenoid (P < 0.001) hypoplasia/aplasia was significantly higher in high-risk patients compared to low-risk.
CONCLUSION: This is one of the largest studies to date evaluating the impact of CF genotype on paranasal sinus development and disease. Genotype appears to impact sinonasal disease severity and also potentially paranasal sinus cavity development to a degree, although the exact mechanism is unknown. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:788-793, 2019.
© 2018 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Cystic fibrosis; genotype; paranasal sinuses

Mesh:

Substances:

Year:  2018        PMID: 30549259     DOI: 10.1002/lary.27595

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.

Authors:  Amanda L Stapleton; Adam J Kimple; Jennifer L Goralski; S Mehdi Nouraie; Barton F Branstetter; Amber D Shaffer; Joseph M Pilewski; Brent A Senior; Stella E Lee; Anna C Zemke
Journal:  J Cyst Fibros       Date:  2022-03-14       Impact factor: 5.527

2.  Analysis of the genotypic profile and its relationship with the clinical manifestations in people with cystic fibrosis: study from a rare disease registry.

Authors:  Senay Rueda-Nieto; Pedro Mondejar-Lopez; María-Pilar Mira-Escolano; Ana Cutillas-Tolín; Luis Alberto Maceda-Roldán; Julián Jesús Arense-Gonzalo; Joaquín A Palomar-Rodríguez
Journal:  Orphanet J Rare Dis       Date:  2022-06-13       Impact factor: 4.303

3.  Sphenoid Bone Pneumatisation on Lateral Cephalograms of Patients With Neurofibromatosis Type 1.

Authors:  Reinhard E Friedrich; Hannah T Scheuer; Jan F Kersten; Hanna A Scheuer
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

Review 4.  Chronic rhinosinusitis in patients with cystic fibrosis-Current management and new treatments.

Authors:  Brian Jake Johnson; Garret W Choby; Erin K O'Brien
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-06-13

Review 5.  Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options.

Authors:  Joanna Krajewska; Krzysztof Zub; Adam Słowikowski; Tomasz Zatoński
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-22       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.